LENZ THERAPEUTICS, INC. Operating Income
LENZ THERAPEUTICS, INC. (LENZ) reported Operating Income of -$34.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$34.17M.
- LENZ THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$44.13M.
- LENZ THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$38.46M.
- LENZ THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$18.89M.
- LENZ THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$91.14M.
- LENZ THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$58.61M.
- LENZ THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$72.43M.
- LENZ THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was -$105.64M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$34.17M 10-Q · filed 2026-08-11 | -$78.31M 10-Q · filed 2026-08-11 | -$116.77M derived: sum of 3 quarters · filed 2026-08-11 | -$135.66M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$44.13M 10-Q · filed 2026-05-11 | -$82.60M derived: sum of 2 quarters · filed 2026-05-11 | -$101.48M derived: sum of 3 quarters · filed 2026-05-11 | -$118.34M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$38.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$57.35M derived: sum of 2 quarters · filed 2026-03-24 | -$74.21M derived: sum of 3 quarters · filed 2026-08-11 | -$91.14M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | -$18.89M 10-Q · filed 2025-11-05 | -$35.74M derived: sum of 2 quarters · filed 2026-08-11 | -$52.67M 10-Q · filed 2025-11-05 | -$67.90M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$16.86M 10-Q · filed 2026-08-11 | -$33.79M 10-Q · filed 2026-08-11 | -$49.01M derived: sum of 3 quarters · filed 2026-08-11 | -$61.96M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$16.93M 10-Q · filed 2026-05-11 | -$32.16M derived: sum of 2 quarters · filed 2026-05-11 | -$45.10M derived: sum of 3 quarters · filed 2026-05-11 | -$59.45M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$15.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$28.17M derived: sum of 2 quarters · filed 2026-03-24 | -$42.52M derived: sum of 3 quarters · filed 2026-03-24 | -$58.61M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | -$12.95M 10-Q · filed 2025-11-05 | -$27.30M derived: sum of 2 quarters · filed 2025-11-05 | -$43.38M 10-Q · filed 2025-11-05 | -$68.37M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$14.35M 10-Q · filed 2025-07-30 | -$30.44M 10-Q · filed 2025-07-30 | -$55.43M derived: sum of 3 quarters · filed 2025-07-30 | -$75.29M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2024-03-31 | -$16.09M 10-Q · filed 2025-05-07 | -$41.08M derived: sum of 2 quarters · filed 2025-05-07 | -$60.94M derived: sum of 3 quarters · filed 2025-05-07 | -$75.90M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | -$24.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$44.85M derived: sum of 2 quarters · filed 2025-03-19 | -$59.81M derived: sum of 3 quarters · filed 2025-03-19 | -$72.43M 10-K · filed 2025-03-19 | -$135.19M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | -$19.86M 10-Q · filed 2024-11-06 | -$25.03M 10-Q · filed 2023-11-13 | -$34.82M derived: sum of 2 quarters · filed 2024-11-06 | -$47.44M 10-Q · filed 2024-11-06 | -$109.64M 10-Q · filed 2023-11-13 | -$74.19M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | -$14.96M 10-Q · filed 2024-08-14 | -$58.16M 10-Q · filed 2023-08-14 | -$27.57M 10-Q · filed 2024-08-14 | -$84.61M 10-Q · filed 2023-08-14 | -$54.33M derived: sum of 3 quarters · filed 2024-08-14 | -$80.48M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$12.62M 10-Q · filed 2024-05-08 | -$26.45M 10-Q · filed 2023-05-11 | -$39.37M derived: sum of 2 quarters · filed 2024-05-08 | -$65.52M derived: sum of 3 quarters · filed 2024-05-08 | -$92.30M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | -$26.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$52.91M derived: sum of 2 quarters · filed 2024-02-27 | -$79.68M derived: sum of 3 quarters · filed 2024-02-27 | -$105.64M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | -$26.15M 10-Q · filed 2023-11-13 | -$52.93M derived: sum of 2 quarters · filed 2023-11-13 | -$78.89M 10-Q · filed 2023-11-13 | -$97.83M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$26.78M 10-Q · filed 2023-08-14 | -$52.73M 10-Q · filed 2023-08-14 | -$71.67M derived: sum of 3 quarters · filed 2023-08-14 | -$86.28M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$25.96M 10-Q · filed 2023-05-11 | -$44.90M derived: sum of 2 quarters · filed 2023-05-11 | -$59.50M derived: sum of 3 quarters · filed 2023-05-11 | -$77.03M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$18.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$33.54M derived: sum of 2 quarters · filed 2023-03-20 | -$51.08M derived: sum of 3 quarters · filed 2023-03-20 | -$60.44M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$14.60M 10-Q · filed 2022-11-09 | -$32.13M derived: sum of 2 quarters · filed 2022-11-09 | -$41.50M 10-Q · filed 2022-11-09 | -$49.83M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$17.53M 10-Q · filed 2022-08-11 | -$26.90M 10-Q · filed 2022-08-11 | -$35.22M derived: sum of 3 quarters · filed 2022-08-11 | -$38.99M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$9.37M 10-Q · filed 2022-05-12 | -$17.69M derived: sum of 2 quarters · filed 2022-05-12 | -$21.45M derived: sum of 3 quarters · filed 2022-05-12 | -$22.75M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$8.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$12.09M derived: sum of 2 quarters · filed 2022-03-21 | -$13.38M derived: sum of 3 quarters · filed 2022-03-21 | -$13.50M 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | -$3.76M 10-Q · filed 2021-11-10 | -$5.06M derived: sum of 2 quarters · filed 2021-11-10 | -$5.18M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$1.29M 10-Q · filed 2021-08-12 | -$1.41M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |